Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Genfit S.A. ADR (GNFT)

Genfit S.A. ADR (GNFT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 160,790
  • Shares Outstanding, K 37,833
  • Annual Sales, $ 45,880 K
  • Annual Income, $ -72,960 K
  • 60-Month Beta 0.68
  • Price/Sales 3.90
  • Price/Cash Flow N/A
  • Price/Book 1.90

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.44
  • Number of Estimates 1
  • High Estimate -0.44
  • Low Estimate -0.44
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.04%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.97 +0.60%
on 09/22/20
5.16 -22.60%
on 08/24/20
-1.19 (-22.90%)
since 08/21/20
3-Month
3.97 +0.60%
on 09/22/20
6.22 -35.79%
on 06/23/20
-1.94 (-32.65%)
since 06/22/20
52-Week
3.97 +0.60%
on 09/22/20
22.48 -82.23%
on 04/21/20
-13.56 (-77.24%)
since 09/20/19

Most Recent Stories

More News
Intercept (ICPT) Posts New Positive Results on NASH Drug

Intercept (ICPT) releases new favorable outcome on OCA from the REGENERATE study, which evaluated patients with liver fibrosis due to NASH.

VKTX : 6.66 (+0.76%)
GLMD : 3.93 (unch)
ICPT : 39.67 (-1.34%)
GNFT : 3.96 (-6.82%)
Intercept's (ICPT) Q2 Earnings and Revenues Beat Estimates

Intercept (ICPT) reports better-than-expected results for the second quarter of 2020.

VKTX : 6.66 (+0.76%)
GLMD : 3.93 (unch)
ICPT : 39.67 (-1.34%)
GNFT : 3.96 (-6.82%)
Is Genfit (GNFT) Stock a Solid Choice Right Now

Genfit (GNFT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

GNFT : 3.96 (-6.82%)
Intercept Down on Postponement of AdCom Meet for NASH Drug

The FDA defers advisory committee meeting date pertaining to Intercept's (ICPT) NDA for obeticholic acid to treat liver fibrosis due to nonalcoholic steatohepatitis.

GILD : 63.61 (-0.93%)
ICPT : 39.67 (-1.34%)
AKCA : 18.15 (+0.06%)
GNFT : 3.96 (-6.82%)
Intercept's (ICPT) Q1 Earnings and Revenues Beat Estimates

Intercept (ICPT) reports better-than-expected results for the first quarter of 2020 on solid Ocaliva sales.

GILD : 63.61 (-0.93%)
AGN : 193.02 (+0.02%)
ICPT : 39.67 (-1.34%)
GNFT : 3.96 (-6.82%)
Why Genfit (GNFT) Stock Might be a Great Pick

Genfit (GNFT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

GNFT : 3.96 (-6.82%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Genfit SA - GNFT

Pomerantz LLP is investigating claims on behalf of investors of Genfit SA ("Genfit" or the "Company") (NASDAQ: GNFT). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com...

GNFTF : 4.7700 (-0.83%)
GNFT : 3.96 (-6.82%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Genfit SA - GNFT

Pomerantz LLP is investigating claims on behalf of investors of Genfit SA ("Genfit" or the "Company") (NASDAQ: GNFT). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com...

GNFTF : 4.7700 (-0.83%)
GNFT : 3.96 (-6.82%)
GNFT ALERT - Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Genfit SA

Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Genfit SA ("Genfit" or the Company") (NASDAQ: GNFT). Investors who purchased Genfit...

GNFTF : 4.7700 (-0.83%)
GNFT : 3.96 (-6.82%)
GNFT ALERT - Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Genfit SA

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Genfit SA ("Genfit" or the "Company") (NASDAQ: GNFT). Investors who purchased Genfit...

GNFTF : 4.7700 (-0.83%)
GNFT : 3.96 (-6.82%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade GNFT with:

Business Summary

Genfit SA is a biopharmaceutical company. It focuses on the discovery and development of therapeutic and diagnostic solutions in metabolic and liver related diseases. The company's lead products include Elafibranor, Nitazoxanide and TGFTX1 which are in clinical stage. Genfit SA is based in Loos, France....

See More

Key Turning Points

2nd Resistance Point 4.48
1st Resistance Point 4.37
Last Price 3.96
1st Support Level 4.18
2nd Support Level 4.10

See More

52-Week High 22.48
Fibonacci 61.8% 15.41
Fibonacci 50% 13.22
Fibonacci 38.2% 11.04
Last Price 3.96
52-Week Low 3.97

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar